Strategies for developing new antibody drugs: the experience in developing anti-IgE for treating asthma and allergy

Tse Wen Chang, Ph.D
Distinguished Research Fellow
The Genomics Research Center cademia Sinica

Education：

National Tsing Hua University, Chemistry B.S., M.S. 1966-72

Harvard University, Cell & Developmental Biology PhD. 1973-77

M.I.T., Immunology Postdoctoral Research 1977-80

Abstract：In this lecture, the speaker will share his experience in creating a new therapeutic concept and bringing it through laboratory research, clinical trials, and finally to broad patients’ use. Two antibodies targeting different antigenic epitopes will be discussed. Today, the anti-IgE antibody, omalizumab (trade name Xolair) has been studied in 128 clinical trials for various allergic and some non-allergic diseases and approved in more than 90 countries to treat patients with severe allergic asthma untreatable with other medicine. The second antibody targets IgE-expressing B cell and has certain advantages over omalizumab. The editor of Nature Biotechnology commented that these programs were good examples of rational drug design approach.

Time:Jun,2th, 2015,10:30

Venue: Medical Science Building, Room B323

Host: Prof. Qingyu Wu & Prof. Xinquan Wang

举办单位：生命科学联合中心